7-Ethoxyrosmanol alleviates hyperglycemia-induced vascular endothelial dysfunction by regulating FBXL7 expression

The current therapeutic strategy for hyperglycemia is reasonable diet and appropriate exercise with drugs, whose outcome is unsatisfied. Therefore, we aimed to explore the new candidate drug 7-Ethoxyrosmanol (7ERM) on hyperglycemia-induced endothelial dysfunction. Human umbilical vein endothelial cells (HUVECs) were treated with different doses of 7ERM in the presence of 33 mM high glucose to measure cell injury, inflammation, and reactive oxygen species (ROS) production. Then F-box/LRR-repeat protein 7 (FBXL7) knockdown by siRNA or overexpressed by plasmid in HUVECs was assessed its effect in the protective role on hyperglycemia-induced endothelial dysfunction. 7ERM time-dependently increased high glucose-induced cell injury, the secretions of pro-inflammatory cytokines and ROS production in HUVECs. Moreover, high glucose time-dependently increased the FBXL7 expressions, which could be gradually inhibited by 7ERM. FBXL7 knockdown ameliorated high glucose-induced cell injury. On the contrary, FBXL7 over-expression inhibited the protective effect of 7ERM on cell injury. In conclusion, 7ERM effectively attenuates high glucose-induced endothelial dysfunction in HUVECs by regulating FBXL7 expression, indicating its potential as a therapeutic drug to treat hyperglycemia.